Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination formulation of **normal saline**, **lidocaine**, and **dexmedetomidine** used for intravenous or local infusion/administration, primarily in perioperative or procedural settings. **Lidocaine** acts as a sodium channel blocker providing local anesthetic and antiarrhythmic effects. **Dexmedetomidine** is a highly selective alpha-2 adrenergic agonist, providing sedation, analgesia, and sympatholytic effects. **Normal saline** serves as the vehicle/diluent for the active drugs. The combination is investigated and utilized for reducing perioperative oxidative stress, minimizing postoperative nausea and vomiting, stabilizing hemodynamics, and providing enhanced analgesia and sedation in various surgical and anesthesia contexts[1][2][3][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on normal saline + lidocaine + dexmedetomidine.